WuXi Bi­o­log­ics serves up $1.4B ex­pan­sion of re­search and man­u­fac­tur­ing cen­ter in Sin­ga­pore

While WuXi Bi­o­log­ics is con­tin­u­ing to work with US reg­u­la­tors on in­spec­tions of its fa­cil­i­ties, the com­pa­ny is al­so look­ing to ex­pand one of its man­u­fac­tur­ing sites in Asia.

On Tues­day, the com­pa­ny an­nounced that it will ex­pand its re­search, de­vel­op­ment, and large-scale drug sub­stance and drug prod­uct man­u­fac­tur­ing ca­pac­i­ty and ca­pa­bil­i­ties in Sin­ga­pore. The ex­pan­sion in­cludes a 10-year, $1.4 bil­lion (S$2 bil­lion) in­vest­ment plan from the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.